Eligible patients were randomly assigned ( 1:1 ) centrally with a minimisation procedure to first-line treatment with gemcitabine ( 1000 mg/m ( 2 ) ) and oxaliplatin ( 100 mg/m ( 2 ) ) with or without cetuximab ( 500 mg/m ( 2 ) ) , repeated every 2 weeks until disease progression or unacceptable toxicity .